*3.1. Patient Characteristics*

A total of 35 NSCLC patients treated with ICI rechallenge between April 2017 and November 2018 at six different institutions in Japan were enrolled. The median age was 70 years (range: 40–83 years), 24 patients (68.6%) were male, and 27 (77.1%) patients had a history of smoking. The histological subtypes were (23, i.e., 65.7%) adenocarcinoma and (10, i.e., 28.6%) squamous cell carcinoma. Metastatic disease was detected in the liver of five patients (14.3%) and in the brain of seven patients (20%). Of the patients, 10 (28.6%) had stage III disease, 19 (54.3%) had stage IV disease, and six (17.1%) had postoperative recurrence at the time of intervention with the initial ICI treatment. An EGFR mutation was detected in four patients (11.4%). There were no ALK-positive patients. ECOG-PS was 0–1 for 23 patients (65.7%) and 2–4 for 12 patients (34.3%). The PD-L1 TPS was ≥50% for 14 patients (50%), 1–49% for eight patients (7%), <0% for seven patients (29%), and not evaluated for six patients (17.1%). The BMI was ≥25 for 3 patients (8.6%), 20–25% for 16 patients (45.7%), and <20 for 16 patients (45.7%). Table 1 shows the baseline characteristics of patients.




**Table 1.** *Cont*.
